Roche Highlights Data from the P-III (STARGLO) Trial of Columvi to Treat Diffuse Large B-Cell Lymphoma at EHA 2024
Shots:
- The P-III (STARGLO) trial is to find the safety, tolerability & efficacy of Columvi + gemcitabine & oxaliplatin (GemOx) vs rituximab + GemOx to treat r/r DLBCL patients administered with at least 1L of therapy & not eligible for autologous stem cell transplant. Trial aims at gaining full approval in the US & EU
- The study, at 11.3mos. of median follow-up, reached the 1EP of OS showing reduced death risk by 41% with mOS not attained vs 9mos.
- The study also reached the 2EPs, depicting PFS of 63%; mOS was 25.5mos. vs 12.9mos. and CR was observed in 58.5% vs 25.3% of patients at a median follow-up of 20.7mos. (patients completed the treatment). Data to be submitted with the regulatory authorities worldwide
Ref: Roche | Image: Roche
Related News:- Roche Reports Data from the P-III Clinical Evaluation of Columvi to Treat R/R Diffuse Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
